An FDA advisory committee will meet today to review
whether the antidepressant Cymbalta should be used as a treatment for
chronic pain, despite risks that include liver damage and skin disease.
Drugmaker Eli Lilly is seeking an indication for use in treatment of
chronic pain, including pain related to arthritis and chronic low back
In briefing documents posted on Tuesday, FDA reviewers said four
studies found Cymbalta worked better than the placebo at easing pain, but